1. Home
  2. ADIL vs FLGC Comparison

ADIL vs FLGC Comparison

Compare ADIL & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals Inc

HOLD

Current Price

$0.30

Market Cap

7.8M

Sector

Health Care

ML Signal

HOLD

Logo Flora Growth Corp.

FLGC

Flora Growth Corp.

HOLD

Current Price

$9.20

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADIL
FLGC
Founded
2010
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
7.6M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ADIL
FLGC
Price
$0.30
$9.20
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$1.50
N/A
AVG Volume (30 Days)
350.0K
16.1K
Earning Date
11-13-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$57,609,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.71
52 Week Low
$0.22
$6.80
52 Week High
$1.30
$81.90

Technical Indicators

Market Signals
Indicator
ADIL
FLGC
Relative Strength Index (RSI) 41.89 46.42
Support Level $0.30 $8.09
Resistance Level $0.33 $13.70
Average True Range (ATR) 0.02 1.11
MACD 0.00 0.60
Stochastic Oscillator 47.05 34.80

Price Performance

Historical Comparison
ADIL
FLGC

About ADIL Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

About FLGC Flora Growth Corp.

Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.

Share on Social Networks: